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Letters to the Editor
Does the presence of adefovir-resistant
variants lead to failure of tenofovir monotherapy?
To the Editor:
With great interest we read the article by Tan and col-
leagues describing their experience of using tenofovir in
patients who experienced treatment failure to adefovir
therapy published in the March 2008 issue of the Journal
of Hepatology [1]. The Authors concluded that combina-
tion therapy of tenofovir with a nucleoside analogue
should be considered in patients with proven ADV-resis-
tance (detection of rtA181 and rtN236 variants). This
recommendation for combination therapies is also in
line with our recently updated national German guide-
lines on the treatment of hepatitis B [2] and is mainly
based on in vitro data showing some level of cross-resis-
tance between tenofovir and adefovir [3–6]. However,
selection of rtA181 variants has not only been described
during adefovir treatment but also during lamivudine
treatment [7]. Moreover, it is not clear if the partial
in vitro cross-resistance between adefovir and tenofovir
also translates to tenofovir treatment failure in vivo as
much higher doses of tenofovir than of adefovir can
be administered. We recently have successfully treated
two adefovir-resistant patients with tenofovir mono-
therapy in whom HBV-DNA became undetectable with-
in less than one year of therapy even though the
rtN236T and/or rtA181V/T variants were present (Ta-
ble 1). In particular, the rapid response of patient 1
seems to be of interest as the A181T variant was de-
tected in this patient. The A181T variant has recently
been described in two patients experiencing viral break-
through during lamivudine and tenofovir or
lamivudine + adefovir + tenofovir treatment [6]. The
rather rapid response to tenofovir monotherapy in our
patients suggests that adefovir had selected for partially
cross-resistant mutants with a defect in viral ﬁtness
which are still susceptible to tenofovir in vivo. If in con-
trast, the ﬁtness of adefovir-resistant mutants is not al-
tered, this may lead to the selection of variants with
secondary resistance mutations leading to tenofovir
monotherapy failure. Only long-term clinical observa-
tion will allow to determine which scenario will hold
true. Villet et al. also reported diﬀerent levels of reduc-
tion in the in vitro susceptibility of A181 variants to ade-
fovir which maybe explained by selection of diﬀerent
additional substitutions in the HBV-RT. [6] To what ex-
tent additional mutations are of importance of suscepti-
bility to tenofovir remains to be determined. In any case,
Table 1
Tenofovir monotherapy in two patients with rtN236T and/or rtA181V/T variants
Patient Previous treatment Variants detected
prior to tenofovir
treatment
Viral load
before tenofovir
(IU/ml)
Viral load
month
4 (IU/ml)
Viral load
month 7
(IU/ml)
Time to
undetectable
HBV DNA-Cobas
TaqMan assay
(<12 IU/ml)
No. 1, male,
58 years
 Lamivudine (duration
11 months)
 Adefovir (duration
10 months)
A181V/T N236T >110 Mill. 2880 41.3 10 months
No. 2, male,
34 years
 Interferon (duration 5 months)
 Lamivudine monotherapy
(duration 34 months)
 Adefovir monotherapy
(duration 29 months)
 Lamivudine + adefovir
combination therapy
(duration 23 months)
A181V 57,600 45.2 28.3 10 months
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controlled clinical trials are warranted to establish the
best possible treatment option for patients with treat-
ment failure to adefovir.
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Pathogenesis of primary sclerosing cholangitis
To the Editor:
We read with great interest the excellent review by
Weismuller et al. [1], recently published in the Journal,
regarding the pathogenesis and management of pri-
mary sclerosing cholangitis (PSC). Although PSC has
been considered an autoimmune disease, because auto-
antibodies are detected frequently, there is neither
consistent nor favorable response to immunosuppres-
sive therapy.
However, as the authors emphasized [1], some exper-
imental studies have supported the hypothesis of an
enterohepatic circulation of long-lived lymphocytes,
which are generated in the gut and translocated to the
liver [2]. This could explain the high frequency of
inﬂammatory bowel disease (IBD) in PSC patients and
why PSC may develop many years after colectomy.
We would like to draw attention to the results of our re-
cently published study [3], which add to and support this
hypothesis(1). In this study [3], we evaluated 53 patients
who underwent liver transplantation (LT) for PSC and
found that after a median time of 60 months after trans-
plantation, 7 of these patients had recurrence of PSC
(rPSC) in the liver graft, based on biochemical, histolog-
ical and radiological ﬁndings. Interestingly, all 7 pa-
tients had ulcerative colitis (UC) and none of them
had undergone total colectomy before LT. In addition,
rPSC did not develop in any of the PSC patients without
UC before or after LT (n = 14), nor in those with pre-
LT total colectomy (n = 6). Thus, it seems that the ab-
sence of UC after LT (due to pre-LT colectomy or
not) is an important factor preventing rPSC. In the uni-
variate analysis, the 7 patients with rPSC, compared to
the 46 without rPSC, had more frequent admissions to
hospital for exacerbations of UC prior to LT, and like-
lihood of having UC (de novo or not) after LT. In addi-
tion, the patients who developed rPSC had more active
UC post-LT as reﬂected by the need for maintenance
steroids given for beyond 3 months from LT. In fact,
the latter parameter was the only variable independently
associated with rPSC. Thus, the development of rPSC
was associated with several factors, all related to the
presence or activity of UC before or after LT. Our study
[3] is the ﬁrst, in which immunosuppressive therapy,
activity of UC and impact of de novo UC after LT were
evaluated in the same cohort.
Our ﬁndings are in keeping with a previous study in
which factors associated with UC were also associated
with rPSC. Vera et al. [4] reported that male gender
and an intact colon post-LT were the strongest predic-
tors of rPSC, and the use of maintenance steroids had
a univariate association. However, it was not stated if
the absence of UC before LT and/or de novo UC post-
LT were associated with rPSC, and the severity of
UC was not found to be associated with rPSC [3]. How-
ever, Graziadei et al. [5] only found a non signiﬁcant
association between the presence of UC and rPSC, but
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